Real-World Use of Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma: A Systematic Review

Abdelrahman  Nanah; Samer Al Hadidi

doi:10.58877/japaj.v1i2.56

Authors

Abdelrahman Nanah Department of Internal Medicine, Cleveland Clinic Fairview Hospital, Cleveland, Ohio
Samer Al Hadidi The University of Arkansas for Medical Sciences

DOI:

https://doi.org/10.58877/japaj.v1i2.56

Abstract

Belantamab mafodotin is an antibody drug conjugate directed against B-cell maturation antigen and was approved by the Food and Drug Administration under accelerated approval for use in the US in August 2020 for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory drug. In November 2022 belantamab mafodotin was withdrawn from the US market after failure of a required confirmatory trial. In our review, we provide a systematic review on the use of belantamab mafodotin efficacy and safety in a real-world setting.

References

Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124(20):3043-3051. doi:10.1182/blood-2014-07-552059

Anderson KC, Kyle RA, Rajkumar S v, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008;22(2):231-239. doi:10.1038/sj.leu.2405016

Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122-1128. doi:10.1038/leu.2013.313

Munshi NC, Anderson LDJ, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705-716. doi:10.1056/NEJMoa2024850

Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314-324. doi:10.1016/S0140-6736(21)00933-8

Moreau P, Girgis S, Goldberg JD. Teclistamab in Relapsed or Refractory Multiple Myeloma. Reply. N Engl J Med. 2022;387(18):1722-1723. doi:10.1056/NEJMc2211969

Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207-221. doi:10.1016/S1470-2045(19)30788-0

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71

Shragai T, Magen H, Lavi N, et al. Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study. Br J Haematol. Published online October 2022. doi:10.1111/bjh.18479

Iula R, Trastulli F, della Pepa R, et al. P20: Polycentric “Real Life” Study of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma. Hemasphere. 2022;6:22-22. doi:10.1097/01.hs9.0000829652.00958.65

de La Rubia J, Alonso R, Clavero Sanchez ME, et al. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort. Blood. 2022;140(Supplement 1):4315-4317. doi:10.1182/blood-2022-158538

Atieh T, Atrash S, Ahmed N, et al. Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. Published online August 2022. doi:10.1016/j.clml.2022.08.003

Alegre A, Benzo Callejo G, Alonso Fernández R, et al. Compassionate Use of Belantamab Mafodotin for Treatment of Patients with Relapsed/Refractory Multiple Myeloma Heavily Treated. Spanish Experience. Blood. 2021;138(Supplement 1):3775-3775. doi:10.1182/blood-2021-151267

Vaxman I, Abeykoon J, Dispenzieri A, et al. “Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience. Blood Cancer J. 2021;11(12):196. doi:10.1038/s41408-021-00592-3

Becnel M, Ferreri CJ, Feng L, et al. Retrospective, single-center, real-world experience of belantamab mafodotin in relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 2022;40(16_suppl):8060-8060. doi:10.1200/jco.2022.40.16_suppl.8060

Mohan M, Rein LE, Thalambedu N, et al. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. Am J Hematol. 2022;97(12):E451-E453. doi:10.1002/ajh.26728

Hultcrantz M, Kleinman D, Vij R, et al. Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study. Blood. 2022;140(Supplement 1):10124-10126. doi:10.1182/blood-2022-164929

Hultcrantz M, Derkach A, Hassoun H, et al. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience. Blood. 2022;140(Supplement 1):7246-7248. doi:10.1182/blood-2022-171077

Roussel M, Texier N, Germain R, et al. Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study. Blood. 2022;140(Supplement 1):4261-4263. doi:10.1182/blood-2022-156035

Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473. doi:10.1038/sj.leu.2404284

Lee L, Bounds D, Paterson J, et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol. 2016;174(6):911-922. doi:10.1111/bjh.14145

Trudel S, Lendvai N, Popat R, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19(12):1641-1653. doi:10.1016/S1470-2045(18)30576-X

Nooka AK, Cohen A, Lee HC, et al. Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial. Blood. 2022;140(Supplement 1):7301-7303. doi:10.1182/blood-2022-164877

Weisel K, Hopkins TG, Fecteau D, et al. Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Participants with Relapsed/Refractory Multiple Myelo. Blood. 2019;134(Supplement_1):1900. doi:10.1182/blood-2019-129893

Lonial S, Nooka AK, Thulasi P, et al. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J. 2021;11(5):103. doi:10.1038/s41408-021-00494-4

Ailawadhi S, Ma Q, Jalbert JJ, et al. Prevalence of ocular comorbidities in patients with multiple myeloma: An analysis of U.S. claims data. Journal of Clinical Oncology. 2022;40(16_suppl):8038. doi:10.1200/JCO.2022.40.16_suppl.8038

Zhang Y, Godara A, Pan S, et al. Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma. Ann Hematol. 2022;101(9):2119-2121. doi:10.1007/s00277-022-04890-z

Khwaja J, Bomsztyk J, Mahmood S, et al. High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis. Blood Cancer J. 2022;12(9):128. doi:10.1038/s41408-022-00717-2

Usmani SZ, Alonso Alonso A, Quach H, et al. DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma. Blood. 2021;138(Supplement 1):2738. doi:10.1182/blood-2021-153315

Rifkin RM, Boyd K, Grosicki S, et al. DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2020;136(Supplement 1):53-54. doi:10.1182/blood-2020-139181

Trudel S, Davis R, Lewis NM, et al. DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2020;136(Supplement 1):4. doi:10.1182/blood-2020-139785

Popat R, Nooka A, Stockerl-Goldstein K, et al. DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2020;136(Supplement 1):19-20. doi:10.1182/blood-2020-139332

Richardson PG, Biswas S, Holkova B, et al. Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 2019;134(Supplement_1):1857. doi:10.1182/blood-2019-129879

Trudel S, Nooka A, Fecteau D, et al. 1105TiP - DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM). Annals of Oncology. 2019;30:v447. doi:https://doi.org/10.1093/annonc/mdz251.039